Drugs in pregnancy.
Koren
G
G
Department of Pediatrics, and the Research Institute, Hospital for Sick Children, University of Toronto, ON, Canada.
Pastuszak
A
A
Ito
S
S
D000014:Abnormalities, Drug-Induced / Q000517:prevention & control*; D000818:Animals; D003376:Counseling; D004025:Dicyclomine; D004319:Doxylamine / Q000009:adverse effects; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D064420:Drug-Related Side Effects and Adverse Reactions; D016021:Epidemiologic Studies; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D007255:Information Services; D015474:Isotretinoin / Q000009:adverse effects; D004364:Pharmaceutical Preparations / Q000145:classification; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011736:Pyridoxine / Q000009:adverse effects; D012306:Risk; D013723:Teratogens / Q000145:classification; D013792:Thalidomide / Q000009:adverse effects
D004338:Drug Combinations; D004364:Pharmaceutical Preparations; D013723:Teratogens; C004454:dicyclomine, doxylamine, pyridoxine drug combination; D004025:Dicyclomine; D013792:Thalidomide; D004319:Doxylamine; D015474:Isotretinoin; D011736:Pyridoxine